Our broad pipeline and innovative drug discovery engine

Our pipeline and drug discovery engine
CSR report

We discover and develop small molecule medicines with novel modes of action, several of which are currently in clinical development in multiple diseases with high unmet medical need. Our highly flexible discovery platform is applicable across many therapeutic areas.

Having achieved approval for the first commercial drug from our novel target platform, we remain highly committed to progressing our deep pipeline of candidates in inflammation, fibrosis, and other indications. With our plans to initiate multiple patient trials in 2021, we set the stage for data-rich newsflow in coming years. Our broad clinical pipeline includes: preferential JAK1 inhibitor filgotinib, which is approved for the treatment of RA in Europe and Japan, filed for approval in UC in Europe, and currently in a Phase 3 trial in CD; GLPG1205, a GPR84 inhibitor which delivered positive topline results in the IPF PINTA Phase 2 trial in 2020; GLPG4716, a chitinase inhibitor inlicensed from  OncoArendi, in preparation for a Phase 2 study in IPF; and the Toledo molecule GLPG3970, a SIK2/3 inhibitor, in Proof of Concept trials in 5 indications. In both our inflammation and fibrosis portfolios we have multiple novel mechanism of action candidates in early research. Almost exclusively these programs are based on inhibiting targets which were identified using our proprietary target discovery platform.

Filgotinib is partnered with Gilead. We have collaborations in place with OncoArendi for GLPG4716, with Fibrocor for GLPG4586 and potentially other assets, and for earlier stage assets with Ryvu and Scipher Medicine. Below is an overview of our current key pipeline assets:

Our clinical pipeline

Our clinical pipeline (graphic)